Novartis’ Aimovig tops topiramate in migraine face-off

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head tri

After rejecting Novartis’ Aimovig for migraine, NICE backs T...

CHMP turns down Lilly’s Emgality for cluster headache

After rejection, NICE agrees to look again at migraine drug ...

Allergan builds case for migraine drug ubrogepant as FDA ver...

Sosei see Teva pipeline cull as an opportunity

Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.